secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001437749-24-009831
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences reports FY2023 net loss of $42.2M; plans $60M rights offering
-------------------------------------------------------------------------------

- GAAP net loss FY 2023 ($42.2M) vs ($58.5M) in 2022; Q4 net loss ($11.9M) vs ($9.2M) prior year.
- Cash and equivalents $44.4M at Dec 31, 2023, down from $61.1M a year earlier.
- FDA 510(k) clearance for CellFX nsPFA Percutaneous Electrode for non-cardiac soft tissue ablation.
- Rights offering of up to $60M in Units (share + warrants) to existing holders; record date in April.
- Chairman Robert Duggan supports and intends to participate in rights offering on same terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924009831/0001437749-24-009831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924009831/plse20240327_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer